The trial, registered prospectively on ClinicalTrials.gov as NCT05408377, enrolled 108 adult women with cyclic mastalgia across three outpatient centers in China. Participants were randomized in a one-to-one ratio to receive either manual acupuncture or sham acupuncture, and both groups followed an identical schedule: 18 sessions delivered over 12 weeks. That design choice matters. By matching the two groups for visit frequency, practitioner attention and the ritual of treatment, the investigators attempted to isolate the specific effect of needling at defined acupuncture points from the considerable placebo and context effects that are known to accompany any hands-on therapy. Of the 108 women who entered the study, 94—87.0 percent—completed the full protocol, a retention rate that lends weight to the results.

The primary endpoint was the change from baseline to week 12 in the Visual Analogue Scale for Breast Pain, or VAS-BP, a standard instrument in which patients rate their pain intensity on a continuous scale. In the intention-to-treat analysis, which included all 108 randomized participants regardless of whether they completed every session, the manual acupuncture group showed a between-group difference of minus 2.0 points at week 12, with a 95 percent confidence interval of minus 2.5 to minus 1.4. In plain terms, women receiving real acupuncture reported substantially less breast pain than women receiving the sham procedure, and the statistical uncertainty around that estimate did not come close to crossing zero. What makes the study unusual is what happened next: at week 36, twenty-four weeks after treatment had ended, the between-group difference was minus 2.2 points, with a confidence interval of minus 2.8 to minus 1.6. The benefit had not faded; it had, if anything, deepened slightly.

Pain intensity is only part of the story for cyclic mastalgia, and the trial’s secondary outcomes addressed the condition’s broader footprint. The number of days of breast pain fell more in the acupuncture group, with a between-group difference of minus 2.0 days at week 12 and minus 3.0 days at week 36. Quality of life, measured with the World Health Organization’s WHOQOL-BREF questionnaire, improved significantly more in the acupuncture group, with a total score advantage of 13.5 points and a physical health domain advantage of 1.0 points. Perhaps most striking for clinicians is the response rate: at week 12, 72.2 percent of women in the manual acupuncture group—39 of 54—were classified as responders, compared with just 22.2 percent—12 of 54—in the sham group. A threefold difference in responder rates between an active treatment and a matched sham control is a large effect by the standards of pain research.

The statistical machinery behind these conclusions was designed to handle the realities of longitudinal clinical data. The investigators used generalized estimating equations, a framework well suited to repeated measurements collected at multiple time points, and they analyzed the data under both intention-to-treat and per-protocol assumptions. Reporting both analyses is important because intention-to-treat preserves the benefits of randomization even when participants drop out, while per-protocol analysis asks what happened among those who actually received the full intervention. The consistency of the results across these frameworks, and the narrow confidence intervals around the primary estimates, suggest the findings are not an artifact of how missing data were handled.

Safety is always a central question for needle-based therapies, and here the trial’s record was reassuring. Three mild adverse events were reported in the manual acupuncture group, and none were reported in the sham group. Mild adverse events in acupuncture trials typically include minor bruising or transient soreness at needle sites, and the low event rate in this study is consistent with the generally favorable safety profile documented for the technique when performed by trained practitioners. For a condition in which standard drug options can carry hormonal side effects, a low-risk non-pharmacological alternative is an attractive proposition, provided the efficacy evidence is credible.

Why might needling at specific points influence cyclic breast pain at all? The trial’s authors are affiliated with acupuncture and moxibustion departments, including the Beijing Key Laboratory of Acupuncture Neuromodulation, and the study sits within a growing research program that seeks mechanistic explanations in neuroscience rather than traditional metaphysics. Pain of hormonal origin involves fluctuating levels of estrogen, progesterone and prolactin acting on breast tissue, and the trial recorded these hormones—estradiol, progesterone and prolactin—among its study variables. Acupuncture is known from other lines of research to engage endogenous opioid and descending pain-modulatory pathways, and neuromodulation at spinal and supraspinal levels can alter how painful signals from the chest wall are processed. Whether such mechanisms fully explain a benefit that persists for six months after treatment ends remains an open question, and the study was not designed to answer it definitively.

The sham-controlled design deserves particular attention, because it is where acupuncture trials most often stumble. Sham acupuncture in such trials typically mimics the sensory experience of treatment—insertion at non-acupoint locations or the use of blunt, retractable needles—so that patients cannot easily tell which arm they are in. The large gap between the two groups in this study, with responder rates of 72.2 percent versus 22.2 percent, suggests the sham procedure did capture much of the ritual of care without reproducing the therapeutic effect. That said, blinding in acupuncture is never perfect: patients may guess their assignment from the presence or absence of deqi sensations, and practitioners cannot be blinded. The authors’ use of a sham rather than a waitlist control strengthens the causal interpretation considerably, but readers should keep these structural limitations in mind.

There are also limits of scope to weigh. The trial was conducted entirely in China, in settings where acupuncture is an established part of routine care, and it is not yet clear whether the same effect sizes would appear in health systems where patient expectations differ. The sample of 108 participants, while adequate for the primary endpoint, is modest, and the study focused specifically on cyclic mastalgia—the cyclical, hormone-linked form of breast pain—rather than non-cyclic pain, which has different underlying mechanisms and may respond differently. The published version notes that the article was shared early as an accepted manuscript subject to further editorial processing, so some details may be refined in the final version of record. None of these caveats, however, undermines the core result of a durable, statistically robust separation between real and sham treatment.

For the millions of women who experience cyclical breast pain severe enough to seek care, the practical message is cautiously encouraging. The trial suggests that a 12-week course of manual acupuncture—18 sessions in all—can deliver relief that outlasts the treatment itself by at least half a year, alongside measurable gains in quality of life, with only mild side effects. It also offers a methodological template: a prospectively registered, sham-controlled, multicenter design with long-term follow-up is exactly the standard that complementary medicine trials need to meet if their results are to change clinical guidelines. Whether acupuncture earns a place alongside analgesics and hormonal agents in the mastalgia treatment algorithm will depend on replication in other populations and on cost-effectiveness analyses, but this study moves the needle—literally and figuratively—toward taking the therapy seriously for a condition medicine has long under-served.

Subject of Research: Long-term efficacy of manual acupuncture versus sham acupuncture for cyclic mastalgia in a multicenter randomized clinical trial

Article Title: The long-term effects of acupuncture for cyclic mastalgia: a multicenter randomized clinical trial

Article References: Yu, C., Shen, B., Li, X., Fang, Y., Xu, L., Han, P., Wang, X., Gao, Y., Zhang, Y., & Guo, J. (2026). The long-term effects of acupuncture for cyclic mastalgia: a multicenter randomized clinical trial. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05622-w

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05622-w

Keywords: acupuncture, cyclic mastalgia, breast pain, sham-controlled trial, randomized clinical trial, pain management, quality of life, VAS-BP, WHOQOL-BREF, complementary medicine, neuromodulation, women's health

The trial enrolled 262 patients with symptomatic paroxysmal or persistent atrial fibrillation and randomised them in a 2:1 ratio to pulmonary vein isolation or to a sham procedure. The primary endpoint was the between-group difference in the change from baseline to six months in the AFEQT summary score, a well-established questionnaire measuring atrial fibrillation-related quality of life. At six months, the mean AFEQT score improved from 61 to 81 in the ablation group and from 59 to 75 in the sham group. Both improvements were clinically meaningful, but the difference in change between the groups was not statistically significant. Meanwhile, ablation demonstrated clear objective efficacy: atrial fibrillation was detected in 21 percent of ablated patients versus 41 percent of sham patients, an absolute difference of 20 percent, with a favourable safety profile.

What distinguishes PVI-SHAM-AF from earlier research is the rigor of its control condition. The sham intervention was not an inert experience but an active clinical pathway encompassing hospital admission, deep sedation and analgesia, venous access, a stay in the catheterization laboratory, cardioversion for patients who arrived in atrial fibrillation, and structured follow-up. The trial therefore tested catheter ablation against this comprehensive procedural and clinical-care package, not against no treatment at all. The investigators emphasise that the study did not evaluate conventional non-invasive ambulatory care. Within the six-month observation window, however, the superior rhythm control achieved by ablation simply did not translate into a statistically significant improvement in patient-reported quality of life beyond what the active sham pathway delivered.

Compared with the two previous sham-controlled ablation trials, SHAM-PVI and PFA-SHAM, PVI-SHAM-AF was substantially larger, exceeding the combined sample size of both predecessors. Baseline quality of life was impaired to a similar degree as in the major open-label trials CABANA and EARLY-AF. Intriguingly, while the improvement within the ablation arms was broadly consistent across all these studies, the improvement observed in the sham arm of PVI-SHAM-AF was markedly lower than in SHAM-PVI and PFA-SHAM. The editorial authors suggest this discrepancy indicates that patient management in PVI-SHAM-AF may have been more comprehensive than in the other two sham trials, intensifying the care received by the control group and thereby narrowing the apparent treatment effect on symptoms.

The findings echo a broader pattern in cardiovascular medicine. Previous reports have documented clinically relevant placebo effects in randomised trials of invasive procedures across settings as varied as resistant hypertension, percutaneous coronary intervention and vertebroplasty for osteoporotic vertebral fractures. A systematic review and meta-analysis found that only about a third of placebo-controlled trials of cardiovascular interventions demonstrated significant superiority of the invasive procedure over placebo. Against this backdrop, PVI-SHAM-AF is less an outlier than a striking confirmation that subjective, patient-reported endpoints are acutely susceptible to contextual healing, expectation and the attention that accompanies any hospital-based intervention.

Why did both groups improve so substantially? The editorial points to a likely combination of placebo and Hawthorne effects, regression to the mean, and optimised concomitant care driven by protocol-adherent assessments and intensive follow-up. Symptoms in atrial fibrillation, the authors argue, may not be determined solely by arrhythmia physiology but also by symptom perception, atrial or ventricular ectopy, anxiety and depression. Quantifying the individual contributions of these mechanisms is difficult, and PVI-SHAM-AF was not designed to isolate them. Disentangling how much of the improvement stems from the procedure itself, from heightened clinical attention, or from psychological factors remains a critical objective for future research and could reshape how symptom-directed therapies are evaluated.

Do the results mean ablation fails to relieve symptoms, or that it should be withheld from patients with preserved left ventricular function? The editorial authors firmly reject both conclusions. The trial demonstrates that ablation reduces atrial fibrillation recurrence and burden safely, and it does not challenge indications in settings where reducing arrhythmia burden may improve clinically relevant outcomes, such as tachycardia-induced or atrial fibrillation-aggravated cardiomyopathy and heart failure with reduced ejection fraction, populations that were not the focus of this study. The results are confined to patient-reported outcomes rather than morbidity or mortality, reflecting a familiar divergence in cardiology where effects on hard endpoints and on how patients feel can part ways, as seen with beta-blockers, inotropes and implantable cardioverter-defibrillators in heart failure.

Questions about patient selection and follow-up duration also deserve scrutiny. Data on the 937 patients who declined randomisation were insufficient for comparison, and willingness to accept an invasive sham procedure may have selected individuals with particular symptom burdens, expectations or treatment preferences; patients with severe symptoms might have declined to guarantee receiving ablation. Yet the mean baseline AFEQT score of 60 mirrored those in CABANA, EARLY-AF and STOP AF First, beta-blocker use remained high and balanced between groups, and no treatment effect heterogeneity by baseline score was observed. The six-month primary endpoint was chosen deliberately to minimise the impact of repeat procedures, but the authors concede it may have been too short to capture the full treatment effect, and it does not exclude longer-term benefits in rhythm control, medication use, healthcare utilisation or clinical outcomes. Twelve-month follow-up is ongoing.

For clinical practice, the implications centre on shared decision-making. PVI-SHAM-AF shows that the objective rhythm-control benefits of catheter ablation should be clearly distinguished from its effects on patient-reported quality of life at six months, information that is essential for counselling patients whose primary goal is symptom relief. The results also underscore the therapeutic power of comprehensive, attentive clinical care. Crucially, the authors stress that invasive sham procedures are research tools for delineating true treatment effects and must never be translated into clinical practice. Instead, the challenge is to identify which components of the sham-associated care pathway improved symptoms and how those elements can be incorporated into routine, non-invasive care.

Perhaps the trial’s most enduring lesson is methodological. The editorial demonstrates that randomised, blinded evaluation of an established, guideline-recommended invasive procedure is accepted by patients, accepted by many expert physicians, and feasible across multiple centres and countries. Sham-controlled designs are particularly important when evaluating subjective or patient-reported outcomes, because such endpoints are vulnerable to placebo effects, expectations, regression to the mean and the effects of intensified clinical care. Just as placebo controls are indispensable for drug therapies, the incremental effect of an invasive or surgical procedure on how patients feel cannot be reliably determined without an appropriate sham control. PVI-SHAM-AF may thus be remembered less for what it says about ablation alone and more for how it resets the standard of evidence for procedural medicine.

Subject of Research: A sham-controlled randomised trial evaluating catheter ablation for symptom relief and rhythm control in patients with symptomatic atrial fibrillation.

Article Title: PVI-SHAM-AF: what does this trial tell us about catheter ablation and symptoms in patients with atrial fibrillation?

Article References: Laufs, U., Böhm, M., Mahfoud, F., & Wachter, R. (2026). PVI-SHAM-AF: what does this trial tell us about catheter ablation and symptoms in patients with atrial fibrillation?. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-03016-z

Image Credits: AI Generated

DOI: 10.1007/s00392-026-03016-z

Keywords: atrial fibrillation, catheter ablation, pulmonary vein isolation, sham-controlled trial, quality of life, AFEQT score, placebo effect, rhythm control, patient-reported outcomes, PVI-SHAM-AF, cardiology, clinical trial